Honorable Ex-Congressman Todd Rokita Joins the Board of Directors of NanoViricides, Inc. SHELTON, CONNECTICUT

Honorable Ex-Congressman Todd Rokita

Joins the Board of Directors of NanoViricides, Inc.

SHELTON, CONNECTICUT -- May 18, 2019 -- NanoViricides, Inc.

(NYSE Amer.: NNVC) (the "Company"), a leader in developing novel nanomedicines

to treat viral diseases, announced today that Honorable Mr. Todd Rokita, J.D., former member of the U.S. House of Representatives

from Indiana, has joined the Company's Board of Directors, effective May 15, 2020, as an independent director. He was also

appointed as a member of the Board's Nomination Committee and Compensation Committee.

Most recently, Mr. Rokita has been nominated by President Trump

to the Board of Directors of the National Railroad Passenger Corporation (aka Amtrak), pending U.S. Senate Confirmation.

He is currently co-owner and General Counsel and Vice President

of External Affairs, Apex Benefits Group, Inc. (2019- Present), where he serves as a member of the executive team and the corporate

Previously, Mr. Rokita was elected to the United States Congress

as a Representative from the State of Indiana, for four consecutive terms since 2010, from the fourth congressional district. He

was chosen by peers in the U.S. House of Representatives to serve on several House Committees.

Mr. Rokita has extensive executive, team-building, business

strategy, and fiscal management expertise in the private sector, alongside his public service leadership experience. Mr. Rokita

serves or has served as a Member of the Board of Directors of several commercial and charitable institutions.

"I believe that having Honorable Mr. Rokita on the Board,

with his vast network, will help NanoViricides achieve its goals of making a difference in the global fight against epidemic viruses,"

said Dr. Makarand Jawadekar, an independent Director of the Company. Dr. Jawadekar introduced Mr. Rokita to the Company. Mr. Rokita

and Dr. Jawadekar have been long term good friends.

The Company believes Mr. Rokita's long history as an executive

and as a board member of a number of institutions and his long record of public service, uniquely qualifies him to serve as a member

of the Company's Board of Directors.

NanoViricides, Inc. (www.nanoviricides.com)

is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide

class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate

is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. The Company is also developing

drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes

keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from

TheraCour Pharma, Inc. The Company does not currently have a license to the coronavirus field, however, TheraCour has not denied

any licenses to the Company. The Company typically begins the licensing process only after demonstrating effectiveness of some

candidates in optimization stage.

This press release contains forward-looking statements that

reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from

those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements

made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act

of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements

since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control

and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company

assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual

results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available

in the future. Important factors that could cause actual results to differ materially from the company's expectations include,

but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents

filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.

Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of

principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our

ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization

of our product candidates; and market acceptance of our products.

As with any drug development efforts, there can be no assurance

that any of these candidates would show sufficient effectiveness and safety for human clinical development at this time.

There can be no assurance that the Company will be successful

in establishing the necessary collaborations, although the Company has been successful at establishing necessary collaborations

for its drug programs in the past.

FDA refers to US Food and Drug Administration. IND application

refers to "Investigational New Drug" application. CMC refers to "Chemistry, Manufacture, and Controls".

Public Relations Contact: